Company Filing History:
Years Active: 2022
Title: The Innovative Contributions of Rene Molina
Introduction
Rene Molina is a notable inventor based in Hagerstown, MD (US). He has made significant strides in the field of cancer treatment through his innovative research and development. His work focuses on creating solutions that enhance the efficacy of oncolytic viruses in combating cancer.
Latest Patents
Rene Molina holds a patent for an "Enveloped virus resistant to complement inactivation for the treatment of cancer." This patent describes a recombinant fusion protein that includes a CD55 peptide sequence, a linker sequence, a transmembrane domain, and an intracellular domain. Notably, the fusion protein does not contain a GPI anchor. It can be expressed with an N-terminal secretory signal peptide, which is cleaved to yield the mature protein on the surface of a cell line or an enveloped virus. The oncolytic virus expressing this fusion protein is resistant to complement inactivation, making it a promising candidate for cancer treatment.
Career Highlights
Rene Molina is currently associated with Wellstat Immunotherapeutics, LLC, where he continues to advance his research in immunotherapy. His work is pivotal in developing innovative treatments that leverage the body's immune system to fight cancer more effectively.
Collaborations
Rene collaborates with talented individuals such as Tianci Luo and Gabriel Castille, who contribute to the research and development efforts at Wellstat Immunotherapeutics, LLC.
Conclusion
Rene Molina's contributions to cancer treatment through his innovative patent and ongoing research highlight the importance of collaboration and creativity in the field of medical science. His work exemplifies the potential of scientific innovation to transform healthcare and improve patient outcomes.